Stockscreener 앱 받기
8.57
3.38%
-0.30
시간 외 거래:
8.75
0.18
+2.10%
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix price target raised to $12 from $11 at RBC Capital - Yahoo Finance
RBC optimistic on CorMedix shares as DefenCath launch gains traction in outpatient - Investing.com Australia
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans - Investing.com Australia
CorMedix Inc. Added to Nasdaq Biotechnology Index - The Manila Times
CorMedix joins Nasdaq Biotechnology Index - Investing.com
CorMedix (CRMD) Earns Coveted Spot in Nasdaq Biotechnology Index in December Update - StockTitan
Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Insider Monkey
CorMedix's SWOT analysis: defencath launch propels stock amid expansion - Investing.com
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark - Simply Wall St
CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com
Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR - GlobeNewswire Inc.
When (CRMD) Moves Investors should Listen - Stock Traders Daily
CorMedix Inc. Announces FDA IND Filing for Neutrolin(R) in United States - Marketscreener.com
CorMedix supports CMS policy updates - TipRanks
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - The Manila Times
CorMedix: Major CMS Policy Change to Boost DefenCath Access for 30% of Dialysis Patients | CRMD Stock News - StockTitan
CorMedix Approves Key Governance and Incentive Changes - TipRanks
Cormedix EVP Elizabeth Hurlburt sells $1.57m in stock - Investing.com India
When the Price of (CRMD) Talks, People Listen - Stock Traders Daily
Nomura Holdings Inc's Strategic Reduction in CorMedix Inc Shares - GuruFocus.com
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Best Momentum Stocks To Buy For November 8th - Barchart
Best Momentum Stocks to Buy for November 8th - Yahoo Finance
Trend Tracker for (CRMD) - Stock Traders Daily
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High? - Yahoo Finance
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium - The Manila Times
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts - Simply Wall St
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic - Yahoo Finance UK
CorMedix: Q3 Earnings Snapshot - AOL
While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
Recent 23% pullback isn't enough to hurt long-term CorMedix (NASDAQ:CRMD) shareholders, they're still up 188% over 1 year - Simply Wall St
CorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call Transcript - Insider Monkey
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - MSN
CorMedix Inc. Reports Q3 2024 Financial Results - TipRanks
CorMedix (CRMD) Q3 2024 Earnings Call Transcript - The Motley Fool
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth By Investing.com - Investing.com South Africa
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth - Investing.com India
CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
2.88%
2.65%
자본화:
|
볼륨(24시간):